a public good project by the
Synthesis
Company
of California

© 2026

Melissa L. Johnson | doi.page

0 works0 citations0 h-index

Melissa L. Johnson

Sarah Cannon Research Institute(GB)Sarah Cannon(US)Tennessee Oncology(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Protein Tyrosine Phosphatases

Most-Cited Works

→ First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer(2018)3,394 cited
→ PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
→ The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,248 cited
→ Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation(2022)908 cited
→ Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer(2020)816 cited
→ Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial(2017)644 cited

→ Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers(2012)

609 cited

→ Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study(2016)544 cited

→ Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial(2023)523 cited

→ Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)(2017)417 cited